OCEA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OCEA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ocean Biomedical's enterprise value is $60.18 Mil. Ocean Biomedical's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-81.06 Mil. Therefore, Ocean Biomedical's EV-to-EBITDA for today is -0.74.
The historical rank and industry rank for Ocean Biomedical's EV-to-EBITDA or its related term are showing as below:
During the past 4 years, the highest EV-to-EBITDA of Ocean Biomedical was 0.28. The lowest was -516.99. And the median was 0.00.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-06-25), Ocean Biomedical's stock price is $1.42. Ocean Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.097. Therefore, Ocean Biomedical's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Ocean Biomedical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocean Biomedical Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
EV-to-EBITDA | - | - | - | - |
Ocean Biomedical Quarterly Data | |||||||||||||||
Dec19 | Mar20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
EV-to-EBITDA | Get a 7-Day Free Trial | - | - | -3.43 | -3.04 | -1.79 |
For the Biotechnology subindustry, Ocean Biomedical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ocean Biomedical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ocean Biomedical's EV-to-EBITDA falls into.
Ocean Biomedical's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 60.182 | / | -81.056 | |
= | -0.74 |
Ocean Biomedical's current Enterprise Value is $60.18 Mil.
Ocean Biomedical's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-81.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocean Biomedical (NAS:OCEA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Ocean Biomedical's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 1.42 | / | -3.097 | |
= | At Loss |
Ocean Biomedical's share price for today is $1.42.
Ocean Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.097.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Ocean Biomedical's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert J Sweeney | officer: Chief Accounting Officer | 20298 CRAIGEN CIRCLE, SARATOGA CA 95070 |
M Michelle Berrey | director | 303A COLLEGE ROAD EAST, PRINCETON NJ 08450 |
William F Owens | director | C/O KEY ENERGY SERVICES, INC., 1301 MCKINNEY STREET, SUITE 1800, HOUSTON TX 77010 |
Inderjote S Kathuria | officer: Chief Strategy Officer | 19W060 AVENUE LATOUR, OAK BROOK IL 60523 |
Gurinder S Kalra | officer: Chief Financial Officer | 2305 WASHINGTON STREET, APT 301, SAN FRANCISCO CA 94115 |
Chirinjeev Kathuria | director | C/O UPHEALTH HOLDINGS, INC., 14000 S. MILITARY TRAIL #203, DELRAY BEACH FL 33484 |
Jerome Ringo | director | 1731 EMBARCADERO ROAD SUITE 200, PALO ALTO CA 94303 |
Poseidon Bio, Llc | 10 percent owner | OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903 |
Daniel Behr | officer: EVP, Innov./Acad. P'ships Head | OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903 |
Jack A Elias | director | OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903 |
Jonathan Kurtis | director | OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903 |
Elizabeth Ng | director, officer: Chief Executive Officer | OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903 |
Martin D Angle | director | OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903 |
Aesther Healthcare Sponsor, Llc | 10 percent owner | 515 MADISON AVE., SUITE 8078, NEW YORK NY 10022 |
Michael L Peterson | director | 17 CANARY COURT, DANVILLE CA 94526 |
From GuruFocus
By GlobeNewswire • 11-29-2023
By Marketwired • 10-03-2023
By sperokesalga sperokesalga • 05-25-2023
By sperokesalga sperokesalga • 06-21-2023
By Marketwired • 06-21-2023
By sperokesalga sperokesalga • 05-16-2023
By Marketwired • 10-04-2023
By sperokesalga sperokesalga • 06-08-2023
By Marketwired • 06-27-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.